NCT01670877: Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT01670877
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Invasive lobular carcinoma
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Therapeutic Antibody, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Diagnosis of ILC not required, but ILC patients are eligible
Exclusions: 
https://ClinicalTrials.gov/show/NCT01670877

Comments are closed.

Up ↑